FORMULATION ARTICLES
-
Suppressor tRNA Therapeutics: A New Frontier In Treating Genetic Disease
Suppressor tRNAs could unlock a scalable new way to treat genetic diseases caused by nonsense mutations, restoring full-length proteins across multiple indications.
-
Engineering Transient In Vivo CAR-T: Extending Expression, Expanding Access, And Rethinking Immune Reset
In this Q&A, Michael Lam, Ph.D., explores how circular RNA and targeted delivery extend transient CAR expression to enable deep B-cell depletion and controllable immune reset.
-
Engineering Repeat-Dose RNA: Engineering Around Immune Recognition In Repeat-Dose RNA Therapeutics
Designing repeat-dose RNA means engineering around immune recognition — optimizing payloads, purity, and delivery early to sustain efficacy, tolerability, and durability across multiple administrations.
-
A Novel Co-Tethered Transcription Platform For High-Yield, High-Purity mRNA Synthesis
Co-tethered transcription boosts mRNA yield and purity by organizing transcription machinery, reducing dsRNA impurities, and streamlining production for scalable RNA therapeutics.
-
A New Approach To RNA Synthesis And Purification: Rethinking A Persistent Bottleneck
Photocleavable supports enable light-triggered RNA release, reducing reliance on chromatography and streamlining synthesis, scalability, and purity for complex RNA therapeutics.
-
Oligos, mRNA, Or Gene Editing: Where Should You Bet?
Investing in RNA and gene editing requires balancing risk, timing, and scale — understanding how oligos, mRNA, and CRISPR each drive value across a converging biotech landscape.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Learn how buffer choice, gradient strategy, and pretreatment steps influence recovery, purity, and resolution when purifying a native RNA oligo, with analytical confirmation and practical guidance.
-
We discuss the process of transfection and highlight two highly effective vectors for both in vitro and in vivo gene therapy applications.
-
Understand the advantages and challenges of lipid-based delivery systems for successful translation of RNA into clinical development.
-
Manual LNP formulation introduces process variability that threatens particle quality and yield. As programs scale toward clinical production, maintaining strict control over CQAs becomes essential.
-
Discover how lyophilization enhances RNA-based therapeutics by enabling storage at higher temperatures, which simplifies cold-chain logistics while preserving nanoparticle integrity and biological activity.
-
Learn about the key stages of drug discovery and screening as well as how to overcome bottlenecks in screening mRNA-LNPs to rapidly develop genomic medicines.
-
Cell therapy’s future depends on smarter gene delivery. Learn how lipid nanoparticles offer a scalable, cell-friendly alternative to electroporation and viral vectors for manufacturing efficiency.